Daniel J. Safer

Daniel J. Safer

Auto-generated profile, based on publicly available information

Daniel J. Safer

Johns Hopkins University School of Medicine, Baltimore, MD, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2008 in Child and Adolescent Psychiatry and Mental Health
Verified
Journal Article
Open access
PDF file
JZJulie Zito
Julie Zito
DSDaniel J Safer
Daniel J Safer
LBLolkje Tw de Jong-Van Den Berg
Lolkje Tw de Jong-Van Den Berg
KJKatrin Janhsen
Katrin Janhsen
Jörg FegertJörg Fegert
Jörg Fegert
SVSatish C Valluri
Satish C Valluri
The study aims to compare cross-national prevalence of psychotropic medication use in youth.

1 March 2006 in Journal of Child and Adolescent Psychopharmacology
Verified
Journal Article
Closed access
DSDaniel J. Safer
Daniel J. Safer
JZJulie Magno Zito
Julie Magno Zito
Objective: The aim of this study was to report the frequency of common treatment-emergent adverse events (AEs) from selective serotonin reuptake inhibitors (SSRIs) in children, adolescents, and adults. Method: AE data were obtained from all published double-blind, placebo-controlled SSRI studies of children and adolescents that separated AE findings by age group. The AE findings were pooled for purposes of age-group comparisons. Double-blind, placebo-controlled SSRI studies of adolescents (n = 2) and of adults identified in systematically identified trials (n = 22) were assessed to compare patterns and rates across the age span. Other reports, primarily from the published SSRI literature, were added to clarify the findings presented. Results: Activation and vomiting SSRI AEs were 2- to 3-fold more prevalent in children than in adolescents, and their rate was lowest in adults. Somnolence as a SSRI AE was uncommon in children; its rate increased with advancing age. Insomnia and nausea were common SSRI AEs across the age span. Activation AEs were a frequent reason for discontinuation from SSRI clinical trials in preadolescents, whereas somnolence, nausea, and insomnia AEs were the most common reasons for trial discontinuations in adults. Conclusions: Children are particularly vulnerable to specific AEs from certain medications, such as SSRIs. It is likely that the level of children's biological immaturity explains part of this phenomenon.

1 March 2003 in American Journal of Psychiatry
Verified
Journal Article
Closed access
DSDaniel J. Safer
Daniel J. Safer
JZJulie Magno Zito
Julie Magno Zito
SDSusan Dosreis
Susan Dosreis

1 August 2004 in Journal of Clinical Psychopharmacology
Verified
Journal Article
Closed access
DSDaniel J. Safer
Daniel J. Safer
A systematic and comprehensive literature search was performed to determine the extent of weight gain induced by risperidone (RIS) treatment across the age span. The review and pooled data analyses were based on double-blind, open trial, and case series studies containing findings on drug dose, age of subjects, weight gain, duration of treatment, and if available, baseline body weight, body mass index, and the percent of subjects experiencing a prominent RIS-induced weight gain. Drug-induced weight gain per month for youths was defined as recorded weight gain minus the age-expected weight gain. The major findings from pooled data were (1) preadolescent youths received a smaller average daily dose and lower mg/kg/d dose of RIS than adolescents, and adolescents in turn had lower mg/kg/d doses than middle-aged adults; (2) RIS-induced weight gain as a percentage of baseline body weight was most pronounced in the preadolescent years and decreased with advancing age; (3) adults over age 65 experienced little to no RIS-induced weight gain; and (4) RIS treatment led to consistently greater body mass index percentage increases for youths than for adults. Available data thus suggest that across the age span, youths are the most sensitive to weight gain induced by a commonly prescribed second-generation neuroleptic.

1 September 2000 in Pediatrics
Verified
Journal Article
Closed access
PDF file
DSDaniel J. Safer
Daniel J. Safer
MMMichael Malever
Michael Malever
Objective.: A statewide school survey was performed to provide naturalistic data on the prevalence of medication administered to Maryland public school students for the treatment of attention deficit hyperactivity disorder (ADHD) to clarify the concern of some state legislators about stimulant treatment for youths.Methods.: In April 1998, school nurses supervised a survey of all Maryland public school students medicated during school hours for ADHD. The data collected on these students included: type of medication administered, gender, school level, race/ethnicity, special education and Section 504 status, and the specialist of the prescriber.Results.: Of the 816 465 students surveyed, 20 050 (2.46%) received methylphenidate and 3721 (0.46%) received other medications for ADHD. Other major findings were: 1) methylphenidate constituted 84% of all the medication administered for ADHD; 2) the male:female ratio of the medication's recipients was 3.5:1 and 4.3:1 in elementary and secondary school, respectively; 3) black and Hispanic students received methylphenidate at approximately half the rate of their white counterparts; 4) 45% of all students receiving methylphenidate had special education status and an additional 8% had Section 504 status; and 5) nurse practitioners were the prescribers of 3% of the methylphenidate prescribed to Maryland students.Conclusions.: This large, population-based, point prevalence study of medication administered to students for ADHD adds new and updated findings on prevalence variations, rates for minority and special education/Section 504 students, and specialty prescriber rates.

15 September 2008 in Child and Adolescent Psychiatry and Mental Health
Verified
Journal Article
Open access
PDF file
JZJulie Zito
Julie Zito
ADAlbert T Derivan
Albert T Derivan
CKChristopher J Kratochvil
Christopher J Kratochvil
DSDaniel J Safer
Daniel J Safer
Jörg FegertJörg Fegert
Jörg Fegert
LGLaurence L Greenhill
Laurence L Greenhill
The review presents pediatric adverse drug events from a historical perspective and focuses on selected safety issues associated with off-label use of medications for the psychiatric treatment of youth. Clinical monitoring procedures for major psychotropic drug classes are reviewed. Prior studies suggest that systematic treatment monitoring is warranted so as to both minimize risk of unexpected adverse events and exposures to ineffective treatments. Clinical trials to establish the efficacy and safety of drugs currently being used off-label in the pediatric population are needed. In the meantime, clinicians should consider the existing evidence-base for these drugs and institute close clinical monitoring.